Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...

Novo Nordisk is also pursuing other indications like liver fibrosis and MASH for semaglutide. (You can read the full research report on Novo Nordisk here >>>) PepsiCo’s shares have ...

In this exclusive interview, Business Today speaks with Vikrant Shrotriya, Managing Director of Novo Nordisk India, about the significance of semaglutide (the active ingredient in Wegovy), its ...

Semaglutide is an injectable medication available as Ozempic and Rybelsus to treat type 2 diabetes and Wegovy for managing overweight or obesity. GLP-1 is a hormone produced by the intestines.

However, at the two-year, three-year, and four-year time points from the index date, those taking semaglutide had an increased risk for NAION (hazard ratios, 2.39, 2.44, and 2.05, respectively).

Novo Banco SA, a Portuguese lender that’s majority-owned by Lone Star, said it’s continuing to prepare for a possible initial public offering, with no exact timing set yet for a sale.

Novo Nordisk, which produces Wegovy and Ozempic ... reports of high chefs designing smaller dishes to cater for semaglutide users, financial pressures mean that this trend has been in motion ...

The factory will cater to various product formats, including GLP-1 medicines such as semaglutide, the active ingredient in Ozempic and Wegovy. Novo Nordisk's investment comes as Brazilian ...

Semaglutide, the active ingredient in Novo's Wegovy and diabetes medicine Ozempic, goes off patent in India in 2026, paving way for generic drugmakers to produce cheaper versions of the drugs.

The 26-week PIONEER 5 trial is one of 10 clinical trials for oral semaglutide that are due to complete this year. Novo's oral semaglutide on target in phase 3 trial | pharmaphorum Skip to main content ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide) significantly reduced the risk of major adverse ...

Novo Nordisk presented additional cardiovascular data this weekend for its blockbuster GLP-1 therapy semaglutide, touting the drug’s potential for addressing cardiometabolic conditions. But analysts ...